Breaking News

A.P. Pharma Cuts Staff

A.P. Pharma, Inc. is reducing its staff by approximately 34% (11 employees) in order to allow for the resources needed to continue advancing its lead program, APF530, towards regulatory approval and commercialization.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

A.P. Pharma, Inc. is reducing its staff by approximately 34% (11 employees) in order to allow for the resources needed to continue advancing its lead program, APF530, towards regulatory approval and commercialization. APF530 is a long-acting formulation of granisetron that uses the company’s Biochronomer drug delivery system. The NDA for APF530 was submitted earlier this month for the prevention of chemotherapy-induced nausea and vomiting (CINV). “A.P. Pharma’s recent NDA submission for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters